AtriCure Inc. (NASDAQ:ATRC) has received an average recommendation of “Buy” from the eight analysts that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $35.75.
Several equities research analysts have weighed in on the company. BidaskClub lowered AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Zacks Investment Research lowered AtriCure from a “buy” rating to a “sell” rating in a research report on Tuesday, March 5th. Finally, BTIG Research reaffirmed a “hold” rating on shares of AtriCure in a research report on Tuesday, March 5th.
Shares of NASDAQ ATRC opened at $29.04 on Friday. AtriCure has a 1-year low of $19.22 and a 1-year high of $36.49. The company has a current ratio of 4.34, a quick ratio of 3.78 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -30.89 and a beta of 0.28.
Hedge funds and other institutional investors have recently modified their holdings of the business. Federated Investors Inc. PA acquired a new position in shares of AtriCure during the third quarter valued at $34,000. PRW Wealth Management LLC acquired a new position in shares of AtriCure during the fourth quarter valued at $61,000. Great West Life Assurance Co. Can increased its holdings in shares of AtriCure by 104.3% during the fourth quarter. Great West Life Assurance Co. Can now owns 4,400 shares of the medical device company’s stock valued at $130,000 after purchasing an additional 2,246 shares during the period. First Quadrant L P CA acquired a new position in shares of AtriCure during the fourth quarter valued at $132,000. Finally, PNC Financial Services Group Inc. increased its holdings in shares of AtriCure by 121.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,331 shares of the medical device company’s stock valued at $133,000 after purchasing an additional 2,373 shares during the period. 89.47% of the stock is currently owned by hedge funds and other institutional investors.
AtriCure Company Profile
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.
Featured Article: What does EPS mean?
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.